Assessment of statin-associated muscle toxicity in Japan: A cohort study conducted using claims database and laboratory information

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Chang, Chia Hsien ^a,b   Kusama, Makiko ^b   Ono, Shunsuke ^b   Sugiyama, Yuichi ^b,c   Orii, Takao ^d   Akazawa, Manabu ^e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

^d Kanto Teishin Hospital   (Japan)

^e MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; CREATINE KINASE; CYCLOSPORIN A; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIAZOLE;

ADULT; ARTICLE; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; JAPAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MUSCLE TOXICITY; MYOPATHY; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; TOXICITY;

EID: 84877670101     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002040     Document Type: Article

References (38)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. (Pubitemid 38924592)
2. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001;61:197-206. (Pubitemid 32210196)
3. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107:433-43. (Pubitemid 46788271)
4. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6. (Pubitemid 27045010)
5. Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18:301-9.
6. Matsuzawa Y, Kita T, Mabuchi H, et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003;67:287-94. (Pubitemid 36417594)
7. Saito M, Hirata-Koizumi M, Urano T, et al. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 2005;30:21-37. (Pubitemid 41602089)
8. Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther 2010;87:714-20.
9. Wang P. Statin dose in Asians: is pharmacogenetics relevant? Pharmacogenomics 2011;12:1605-15.
10. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: An assessment using an administrative claims database. Am J Cardiol 2006;97:61C-8C.
11. Molokhia M, McKeigue P, Curcin V, et al. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS ONE 2008;3:e2522.
12. Robb MA, Racoosin JA, Sherman RE, et al. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 2012;(Suppl 1):9-11.
13. Pharmaceuticals and Medical Devices Agency. MIHARI project. Tokyo, Japan, 2011. http://www.pmda.go.jp/english/service/mihari-project.html (accessed 31 Aug 2012).
14. Kimura T, Matsushita Y, Yang YH, et al. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan. Pharmacoepidemiol Drug Saf 2011;20:1237-45.
15. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (accessed 31 Aug 2012).
16. Hashikata H, Harada KH, Kagimura T, et al. Usefulness of a large automated health records database in pharmacoepidemiology. Environ Health Prev Med 2011;16:313-19.
17. Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: An observational study using a Japanese hospital database. PLoS One 2012; 7:e53224.
18. Japanese Ethical Guidelines for Epidemiological Research. (In Japanese). 2008. http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ekigaku/0504sisin.html (accessed 31 Aug 2012).
19. Okuno J, Yanagi H, Tomura S, et al. Compliance and medication knowledge among elderly Japanese home-care recipients. Eur J Clin Pharmacol 1999;55:145-9.
20. Ohta Y, Tsuchihashi T, Onaka U, et al. Long-term compliance of salt restriction and blood pressure control status in hypertensive outpatients. Clin Exp Hypertens 2010;32:234-8.
21. Pharmaceutical and Medical Devices Agency. PMDA package insert database for medicine product approved in Japan. 2012. (in Japanese). http://www.info.pmda.go.jp/info/iryo-index.html (accessed 31 Aug 2012).
22. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90. (Pubitemid 39577514)
23. Amend KL, Landon J, Thyagarajan V, et al. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother 2011;45:1230-9.
24. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89C-94C.
25. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus (in Japanese). J Jpn Diabetes Soc 2010;53:450-7.
26. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90. (Pubitemid 350137473)
27. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17. (Pubitemid 32678717)
28. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-14. (Pubitemid 46149563)
29. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41. (Pubitemid 41393668)
30. Alford JC, Saseen JJ, Allen RR, et al. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy 2012;32:623-30.
31. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:27C-31C.
32. Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: A retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2012;21:494-506.
33. Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997;127:666-74.
34. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: A VA-Adapted pharmacy-based case-mix instrument. Med Care 2003;41:761-74.
35. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236-42.
36. Tuckuviene R, Christensen AL, Helgestad J, et al. Paediatric arterial ischaemic stroke and cerebral sinovenous thrombosis in Denmark 1994-2006: A nationwide population-based study. Acta Paediatr 2011;100:543-9.
37. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients -A nationwide cohort study. PLoS ONE 2011;6:e21368.
38. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012;366:1467-76.